FOXN1D Potentiates PKM2-Mediated Tumor Glycolysis and Angiogenesis

Wei Zhang

Fudan University Institutes of Biomedical Sciences

Xin Zhang

Fudan University Institutes of Biomedical Sciences

Sheng Huang

Fudan University Shanghai Cancer Center Department of Radiation Oncology

Jianfeng Chen

Fudan University Institutes of Biomedical Sciences

Peipei Ding

Fudan University Institutes of Biomedical Sciences

Qi Wang

Fudan University Institutes of Biomedical Sciences

Luying Li

Fudan University Institutes of Biomedical Sciences

Xinyue Lv

Fudan University Institutes of Biomedical Sciences

Ling Li

Fudan University Institutes of Biomedical Sciences

Pingzhao Zhang

Fudan University Institutes of Biomedical Sciences

Danlei Zhou

Fudan University Institutes of Biomedical Sciences

Wenyu Wen

Fudan University Institutes of Biomedical Sciences

Yiping Wang

Fudan University Institutes of Biomedical Sciences

Qunying Lei

Fudan University Institutes of Biomedical Sciences

Jiong Wu

Fudan University Shanghai Cancer Center

Weiguo Hu (✉ weiguohu@fudan.edu.cn)

Fudan University Institutes of Biomedical Sciences <https://orcid.org/0000-0002-7397-6800>

Research

Keywords: PKM2, FOXM1D, Glycolysis, Angiogenesis, NF- κ B, Importin 4, VPS11, Exosome

Posted Date: July 6th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-40077/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Molecular Oncology on April 2nd, 2021. See the published version at <https://doi.org/10.1002/1878-0261.12879>.

Abstract

Background: Tumor growth, especially in the late stage, requires adequate nutrients and rich vasculature, in which PKM2 plays a convergent role. It has been reported that PKM2, together with FOXM1D, is upregulated in late stage colorectal cancer and associated with metastasis; however, their underlying mechanism for promoting tumor progression remains elusive.

Methods: Western blot, coimmunoprecipitation (Co-IP), glutathione S-transferase (GST)-pull down and Immunofluorescence (IF) were performed to investigate the interaction between FOXM1D with PKM2 and other proteins. Extracellular acidification (ECAR) and oxygen consumption rate (OCR) assays, Protein Cross-linking, Gel chromatography, Pyruvate Kinase (PK) activity assay were used to examine the effect of FOXM1D on glycolysis. The angiogenesis effect was verified by Human umbilical vein endothelial cell (HUVEC) tube formation assay, tumor tissue microangiography, VEGFA Elisa assay and ChIP assay.

Results: FOXM1D potentiates PKM2-mediated glycolysis and angiogenesis through multiple protein-protein interactions. In the presence of FBP, FOXM1D binds to tetrameric PKM2 and assembles a heterooctamer, restraining PKM2 metabolic activity by about a half and thereby promoting aerobic glycolysis. Furthermore, FOXM1D interacts with PKM2 and NF- κ B and induces their nuclear translocation with the assistance of the nuclear transporter importin 4, which subsequently augments *VEGFA* transcription that is regulated by the PKM2 and NF- κ B complex. The increased VEGFA is secreted extracellularly via exosome, which is potentiated by the interaction of FOXM1 with VPS11, eventually promoting tumor angiogenesis.

Conclusion: Our study indicates that FOXM1D plays a crucial role in promoting glycolysis and angiogenesis through its protein-protein interaction. The above findings provide another insight into the role of PKM2 in the regulation of glycolysis and angiogenesis.

Background

Late stage cancer frequently indicates a large tumor size accompanied by metastasis to nearby tissues, lymph nodes, or even other distant organs. This then leads to a poor therapeutic response and prognosis due to the limited number of available treatment regimens. Therefore, the investigation of the late stage cancer still presents an unmet need. Angiogenesis, the process of forming new vascular networks, is required to supply adequate oxygen and nutrients to support tumor proliferation and further metastasis [1]. The production of nutrients and the formation of vasculature are prerequisites for the uncontrolled and rapid proliferation that is a hallmark of cancer cells. In order to sustain this level of metabolism, cancer cells must convert large amounts of glucose to lactate even in the presence of oxygen, a process that is termed the Warburg effect or aerobic glycolysis [2, 3]. This may facilitate tumor growth by producing more glucose metabolites for the synthesis of macromolecules [3–6]. PK kinase regulates the final step of glycolysis by transferring a phosphate group from phosphoenolpyruvate (PEP) to adenosine diphosphate (ADP) to produce pyruvate and adenosine triphosphate (ATP) [7]. Due to alternative splicing

[8, 9], there are four PK isoforms [10, 11], i.e., PKM1, PKM2, PKL and PKR, in which PKM2 is the primary type expressed and up-regulated in tumor cells [12]. In the cytoplasm, PKM2 normally presents in either a homotetramer form that allows for the highly effective conversion of glucose to lactate, acting as a metabolite kinase, or a low activity homodimer form that uses PEP as a phosphate donor to phosphorylate tyrosine residues, acting as a signal transducer and activator of transcription [10, 13]. Upon upstream stimulus, such as epidermal growth factor (EGF) or interleukin-3, PKM2 also translocates into the nucleus to play a non-metabolic role as a histone kinase and/or a transcriptional coactivator, thus promoting the Warburg effect and cell cycle progression via cyclin D1 and β -catenin [14–18].

In order to facilitate angiogenesis, cancer cells frequently overexpress proangiogenic factors, for example vascular endothelial growth factor-A (VEGFA), thereby positioning antiangiogenic agents as potential strategies for tumor therapy. However, the current drugs targeting the VEGF pathway, including bevacizumab and sorafenib, have displayed only a limited antitumor effect in certain settings [19], prompting the need to understand the contribution of angiogenesis in tumors and the molecular mechanisms by which it acts. Hypoxia-inducible factor 1 (HIF-1 α) has shown indication as one of the important links between angiogenesis and glycolysis. HIF-1 α promotes PKM2 transcription, and inversely, PKM2 interaction with HIF-1 α enhances HIF-1 α -dependent gene transcription [20, 21]. Furthermore, in hypoxic pancreatic tumors both HIF-1 α and NF- κ B together regulate the transcription and secretion of VEGFA, which is controlled by PKM2 translocated to the nucleus [22]. In addition, it has been reported that PKM2 regulates angiogenesis mediated by the NF- κ B p65 subunit, although the underlying mechanisms remain largely obscured [23].

Forkhead box M1 (FOXM1) was initially defined as a transcription factor by containing a common DNA-binding domain termed the forkhead box [24]. It is strongly upregulating in almost all types of tumors and highly correlating with tumor progression [25, 26]. Due to alternative splicing, there are four FOXM1 isoforms, FOXM1A/B/C/D [27, 28]. FOXM1B/C mainly locate in the nucleus and function as a transcription factor by controlling over 200 genes that are mainly involved in cell proliferation [29, 30]. It has been recognized as a major predictor (actually indiscriminately referred to as FOXM1) of adverse outcomes in cancer by gene landscape analysis [26, 31]. In contrast, FOXM1A/D exist predominantly in the cytoplasm without direct transcription-regulating functions. FOXM1A has been almost ignored, likely due to its low level of expression [28, 32]. Meanwhile, FOXM1D, which we recently identified is highly expressed only in late stage colorectal cancer, was found to promote the cancer epithelial–mesenchymal transition (EMT) and metastasis by interacting with ROCKs [28]. In this study, we found that FOXM1D also interplays with multiple proteins including PKM2, importin 4, NF- κ B, and VPS11, it promoting aerobic glycolysis through assembly a heterooctamer with PKM2, which enhances angiogenesis by increasing the expression and release of VEGF.

Result

Identification of the FOXM1D and PKM2 Interaction

In late stage colorectal cancer, FOXM1D, a new isoform of FOXM1, promotes tumor metastasis by binding to and further activating ROCKs [28]. In our study, we found that anti-Flag antibody immunoprecipitated more proteins, including PKM2 rather than ROCK2, in the Co-IP assay and subsequent mass spectrometric analysis of HeLa cells overexpressing Flag-FOXM1D (Fig. 1a, and Additional file 4: Supplementary Data). Next, we confirmed the interaction between PKM2 and FOXM1D by mutual Co-IP analysis using anti-Flag and anti-HA antibodies in 293T cells transfected with HA-PKM2 and Flag-FOXM1D (Fig. 1b). The result of GST-pulldown assay also demonstrated this interaction. GST-FOXM1D pulled down HA-PKM2 expressed in 293T cells, which was determined by both anti-HA and anti-PKM2 antibodies (Fig. 1c).

To explore the precise binding region between FOXM1D and PKM2, we designed truncated mutants based on the structural domain of PKM2 (Fig. 1d) [33], and further expressed them with HA tag in 293T cells (Fig. 1e). The result of a Co-IP assay using anti-HA antibody demonstrated that PKM2 mutants A, B, and C, as well as intact PKM2 could capture the co-expressed Flag-FOXM1D (Fig. 1e), indicating that the domains A1 and/or B of PKM2 are most likely the binding site for FOXM1D. We further identified the precise binding region in PKM2 using the GST-pulldown assay. As shown in Fig. 1f, GST-FOXM1D bound to the B but not the A1 domain of PKM2, as expressed in 293T cells. In addition, we also designed truncated mutants of FOXM1D that were based on the coding exons due to absence of the FOXM1 crystal structure (Fig. 1g) [28]. We expressed these with Flag tag in 293T cells, and using the Co-IP assay with the anti-Flag antibody we mapped the binding mutants of FOXM1D to the co-expressed PKM2 as mutant A, B, and D (Fig. 1h). Our findings suggested that exon II and III of *FOXM1D* encoded the binding region for PKM2, therefore clearly demonstrated the interaction between FOXM1D and PKM2.

FOXM1D Promotes Tumor Aerobic Glycolysis

Given that exons II and III of *FOXM1D* are shared by *FOXM1A/B/C/D* [28], we thus detected whether or not FOXM1A/B/C could physically bind to PKM2. We co-transfected 293T cells with plasmid expressing HA-PKM2, Flag-FOXM1A/B/C/D, or empty vector, then performed a Co-IP assay using anti-Flag antibody. As we expected, all of the four Flag-tagged FOXM1 isoforms bound to HA-PKM2 (Additional file 1: Fig. S1a) and exhibited little effect on the transcription of PKM2 (Additional file 1: Fig. S1b). Because PKM2 catalyzes the rate-limiting step of aerobic glycolysis, it plays a crucial role in the regulation of the Warburg effect [4, 34]. As FOXM1A/B/C/D all interact with PKM2, we sought to detect the effect of ectopic expression of FOXM1A/B/C/D on glycolysis by measuring the ECAR and OCR in HeLa cells. FOXM1D induced an appreciable increase in ECAR, which reflects overall glycolytic flux (Fig. 2a), along with a decrease in OCR, which is an indicator of mitochondrial respiration (Fig. 2b). Meanwhile FOXM1A/B/C failed to induce an obvious alteration in either ECAR or OCR when compared to the vector control (Fig. 2a-b). Considering that LoVo and SW-480 cells display the highest and lowest expression levels of FOXM1D, respectively, in the six examined colorectal cell lines [28], we further compare the effect of FOXM1D on glycolysis between them. We measured the ECAR and OCR in SW-480 cells that over-expressed FOXM1D and in LoVo cells where FOXM1D was knocked down by specific siRNA. We found that ectopic FOXM1D resulted in a notable elevation in the ECAR, whereas insufficient FOXM1D resulted

in an ECAR reduction (Fig. 2c). In contrast, ectopic FOXM1D yielded a significant reduction in the OCR, while insufficient FOXM1D resulted in its elevation (Fig. 2d). Together, these results demonstrated that FOXM1D could effectively promote the Warburg effect.

FOXM1D Inhibits PK Activity of PKM2 Tetramer by Assembling a Heterooctamer

It has been reported that PK activity of PKM2 may be regulated by its post-translation modification (PTM). Phosphorylation at Y105 may inhibit the formation of the active PKM2 tetramer [35], acetylation at K305 may increase PKM2 degradation [13], and acetylation at K433 may interfere with FBP binding [7]. Considering that FOXM1A/D, but not FOXM1B/C, significantly regulate glycolysis without changing the PKM2 expression level as described previously, we first detected the PTM status of PKM2 by immunoblotting in HeLa cells with ectopic FOXM1A/D expression. The results showed that the levels of phospho-Y105, acetyl-K305 and -K433 unchanged after ectopic FOXM1A/D expression (Fig. 3a), indicating that another mechanism was involved in the regulation of glycolysis. In addition, we found that ectopic FOXM1A/D expression failed to change the level of phospho-S37 of PKM2, which is associated with nuclear translocation [15] (Fig. 3a).

The PK activity of PKM2 is also allosterically activated by FBP, whose binding to PKM2 causes the switch from a less active monomeric/dimeric form to an active tetrameric form [18, 36, 37]. Next, we determined the monomer: dimer: tetramer equilibrium of PKM2 using cross-linking experiments with glutaraldehyde in HeLa cells with ectopic FOXM1A/D expression. Following glutaraldehyde cross-linking, the proportion of the tetramer in FOXM1D-overexpressing cells was notably reduced, while the monomer increased when compared with FOXM1A-overexpressing and control cells (Fig. 3b). Interestingly, we observed that an obvious band ran close to the location of stacking gel (arrow in Fig. 3b). To understand whether or not this macromolecular band was associated with the complex of PKM2 and FOXM1D, we induced PKM2 insufficiency (Fig. 5j) by using two specific siRNAs in HeLa cells with ectopic FOXM1A/D (up panel in Fig. 3c). Immunoblotting assays using anti-FOXM1 antibody revealed the presence of another notable band, other than a normal FOXM1 band, that was also located close to the stacking gel in the cell extracts treated with glutaraldehyde. This band was present in both the scramble siRNA treated HeLa cells (left bottom panel in Fig. 3c). However, PKM2 insufficiency provoked this band much weaker only in FOXM1D- but not FOXM1A-overexpressing cells compared to scramble control, thus resulting in a dissociated new band close to the normal FOXM1 (middle and right bottom panels in Fig. 3c). These results suggested that FOXM1D, but not FOXM1A, could form a large heterogeneous polymer with PKM2 to regulate glycolysis.

In order to determine the size and composition of the heterogeneous polymer, we used gel chromatography to separate FOXM1D and PKM2 in the extract of FOXM1A/D-overexpressing HeLa cells. The result of the immunoblotting assay for each fraction demonstrated that FOXM1D, PKM2, and FBP appeared simultaneously in fractions 28-35, whose size was a bit greater than the 660 kD marker in the fraction between 35 and 36 (Fig. 3d). The four B domains of the PKM2 tetramer were located at the outside corner [38], and the binding site of FOXM1D on PKM2 was located in the B domain, both of which

may favor the binding of four FOXM1D molecules to the PKM2 tetramer without steric hindrance. Therefore, we hypothesized that this heterogeneous polymer was most likely a heterogeneous octamer, i.e., a complex of four PKM2 (~60 kD), four FBP (~40 kD), and four FOXM1D (apparent ~130 kD). In addition, we observed that ectopic FOXM1D decreased the proportion of PKM2 tetramer accompanied by the reduced FBP (fractions 43-47), and increased those of the PKM2 dimer (fractions 48-52) and monomer (fractions 53-54) when compared with the vector control (Fig. 3d). It is notable that FOXM1A failed to form such a heterogeneous octamer with PKM2 in fractions 28-35 (Additional file 1: Fig. S2), indicating that this physical interaction may be unstable. In addition, ectopic FOXM1A seemed to result in a slight increase in the proportion of PKM2 tetramer, accompanied by an increase in FBP (fractions 43-47) and PKM2 dimer (fractions 48-52) and a reduction of PKM2 monomer (fractions 53-54) (Additional file 1: Fig. S2).

Given that the PKM2 tetramer displayed high PK activity, we next measured the enzyme activity of each fraction. The results showed that the heterogeneous octamer, which existed in fractions 28-33 in the extracts of FOXM1D-overexpressing HeLa cell, showed undetectable PK activity (Fig. 3e). The PK activity of fractions 43-52, which contained PKM2 tetramer and dimer, decreased in the extracts of FOXM1D-overexpressing compared with FOXM1A-overexpressing and control HeLa cells (Fig. 3e). Interestingly, we found that fractions 38-42 from the extracts of the FOXM1A-overexpressing and control, but not FOXM1D-overexpressing HeLa cell displayed notable PK activity (Fig. 3e). This PK activity may result from the complex of PKM2 tetramer and other proteins, as FBP existed in these fractions and FOXM1D may have disrupted this complex (Fig. 3d).

To further confirm the physical interaction between FOXM1A/D and PKM2, we expressed and purified recombinant Flag-FOXM1A/D and Flag-FBP, and purchased PKM2. The results of SDA-PAGE (Additional file 1: Fig. S3a) and gel chromatography (Additional file 1: Fig. S3b-e) demonstrated the high purity and the principal existence form of the monomer. In the presence of excess FBP, the tetramer is the predominant form of PKM2, with trivial amount of monomer and without the dimer forms (Additional file 1: Fig. S3f). However, in the absence of FBP but the presence of FOXM1A or FOXM1D, PKM2 formed a heterodimer with FOXM1A (Additional file 1: Fig. S3g) or FOXM1D (Fig. 3f). Furthermore, in the presence of both FBP and FOXM1A, PKM2 preferred to form a homologous tetramer exclusive of binding to FOXM1A, although we did observe a tiny heterooctamer curve (Additional file 1: Fig. S3h). In contrast, in the presence of FBP and FOXM1D, all of the PKM2 tetramer further bound to the four molecules of FOXM1D, leading to the assembly of a heterooctamer (Fig. 3g). This finding indicated that FOXM1D and FOXM1A displayed different binding activity to PKM2 tetramer. In the functional test, supplement of FBP alone, but not FOXM1A or FOXM1D alone, elevated the PK activity of PKM2 remarkably (Fig. 3h). Addition of FOXM1A weakly elevated the above FBP-induced PK activity of PKM2 but without statistical significance, however, addition of FOXM1D significantly reduced this PK activity in a dose-dependent manner (Fig. 3h). Moreover, when providing excessive FOXM1D (1.33-fold of PKM2 in molar ratio), about half (49%) of the PK activity of PKM2 was abolished. Therefore, these findings reveal that FOXM1D binds to the PKM2 tetramer to assemble a heterogeneous octamer, thereby reducing PK activity by about a half.

FOXM1D Promotes Tumor Angiogenesis

It has been recognized that the Warburg effect is closely associated with tumor angiogenesis [39-41], however, the underlying mechanisms remains elusive. Therefore, we detected the effect of ectopic FOXM1D expression on tumor angiogenesis. We collected the supernatant of FOXM1A/B/C/D-overexpressed or control HeLa cells, then used those to treat HUVECs before detecting the ability for tube formation. The results showed that ectopic expression of only FOXM1D, but not of FOXM1A/B/C and control significantly enhanced angiogenic sprouting and tube formation in HUVECs (Fig. 4a-c). This finding indicating that the supernatant of FOXM1D-overexpressing HeLa cells may contain pro-angiogenesis factor(s).

To verify this angiogenic effect *in vivo*, we qualified the tumor blood vessels by microangiography [42]. Considering that FOXM1B accelerates tumor growth more potently than FOXM1D [28], we selected tumor tissues of similar sizes to compare their microvessels. These tumor tissues were collected from previously generated tumor-bearing mice that were implanted with vector control, FOXM1B-, or FOXM1D-overexpressing HeLa cells [28]. The images of tumor blood vessels show that ectopic FOXM1D, but not FOXM1B visibly enhanced angiogenesis compared to vector control (Fig. 4d). Furthermore, the quantitative results revealed that, although the tumor sizes were comparable in each group, the density, branches, nodes, maximal diameter, and average diameter of the microvessels in FOXM1D-, but not FOXM1B-overexpressing tumors were significantly greater than those of vector control tumors (Fig. 4e). Together, these results suggested that FOXM1D may strongly promote tumor neovascularization, most likely through releasing the pro-angiogenesis factor, and more importantly, that the ample number of blood vessels induced by ectopic FOXM1D expression failed to accelerate tumor growth synchronously.

FOXM1D Upregulates VEGFA Expression Mediated by PKM2 and NF- κ B

VEGF/VEGF-receptor signaling has been well-established as a key mediator of tumor angiogenesis [43]. Therefore, to understand the molecular mechanism of the FOXM1D angiogenic effect and its relationship with PKM2-mediated glycolysis, we first detected the expression level of VEGFA in the cell lysate of FOXM1D-overexpressing HeLa cells. Unexpectedly, ectopic FOXM1D even reduced the VEGFA level compared to vector control (Fig. 5a). However, we observed that VEGFA levels were significantly increased in the supernatants of FOXM1A/D- but not of FOXM1B/C-overexpressing HeLa cells (Fig. 5b). This result indicated that, in FOXM1D-overexpressed HeLa cells, VEGFA was most likely secreted extracellularly. Although FOXM1B has been reported to increase *VEGF* transcription in glioma cells [44], we observed that only FOXM1D, but not FOXM1A/B/C caused a marked upregulation in *VEGFA* transcription as detected by quantitative real-time PCR (qRT-PCR) (Fig. 5c).

Considering the facts that: 1) nuclear PKM2-controlled HIF-1 α and NF- κ B regulate VEGFA transcription in hypoxic conditions [22]; 2) nuclear PKM2 promotes angiogenesis by directly interacting with the NF- κ B p65 subunit [23]; 3) FOXM1 directly interacts with the NF- κ B subunit p65 [45]; and 4) FOXM1D, PKM2, and p65/p50 co-existed in fractions 34-36 in the gel chromatography experiment (Fig. 3d), we therefore hypothesized that FOXM1D may promote *VEGFA* transcription by interacting with PKM2 and NF- κ B.

Although we previously failed to identify any NF- κ B subunits as FOXM1D binding proteins by Co-IP and LC/MS analysis (Additional file 4: Supplementary Data), we still conducted the Co-IP assay in order to detect the interaction between FOXM1A/B/C/D and NF- κ B. In the vector control and Flag-FOXM1A/B/C/D-overexpressing HeLa cells, we further transfected HA-p65 or -p50 expressing plasmid. The results of the Co-IP assay revealed that anti-Flag antibody captured HA-tagged p65 and endogenous PKM2 in all of the FOXM1A/B/C/D-overexpressing cells (Fig. 5d-e), while it could capture HA-tagged p50 only in Flag-FOXM1A-, and especially Flag-FOXM1D-overexpressing cells (Fig. 5e). In addition, anti-HA antibody captured Flag-tagged FOXM1A/B/C/D in HA-p65-overexpressing cells (Fig. 5d) and endogenous PKM2 in either HA-p65- or HA-p50-overexpressing cells (Fig. 5d-e), however, anti-HA antibody bound only slightly to Flag-FOXM1A, but bound strongly to Flag-FOXM1D (Fig. 5e). Furthermore, both nuclear subunits p65 and p50 increased simultaneously in HeLa cells with ectopic expression of FOXM1A/B/C/D (Fig. 5f), resulting in the reduced levels of p65 and p50 in cytoplasm but not in total cell lysate (Additional file 1: Fig. S4). These results suggest that FOXM1D may up-regulate VEGFA transcription by promoting NF- κ B nuclear translocation.

Next, we detected the effect of PKM2, the critical regulator in glycolysis, on FOXM1D-induced *VEGFA* transcription. Two specific siRNAs against PKM2 reduced *PKM2* mRNA levels. However, si-PKM2 #1 induced the restoration of *PKM1* mRNA, while si-PKM2 #2 downregulated *PKM1* transcription (Fig. 5g). We further observed that the PKM2 insufficiency induced by two siRNAs almost completely abrogated FOXM1D-induced *VEGFA* transcription (Fig. 5h), secretion (Fig. 5i), and translation (Fig. 5j) in FOXM1D-overexpressed cells. Therefore, PKM2 may effectively regulate VEGFA expression independent of PKM1.

To confirm that PKM2 and NF- κ B may regulate *VEGFA* transcription as transcriptional factors, we conducted a ChIP assay in FOXM1D-overexpressing HeLa cells in order to identify whether or not PKM2 and NF- κ B bind directly to the same *VEGFA* promoter region. The specific antibody against PKM2, p50, or p65, but not isotype IgG enriched this promoter fragment remarkably (Fig. 5k-m), which was amplified by qRT-PCR with the same primer pair (Fig. 5k). We further knocked-down the expression of PKM2 and p65 to verify the binding specificity. Insufficiency of PKM2 significantly impaired the capability of enriching the *VEGFA* promoter fragment not only by PKM2 antibody but also by p65 or p50 antibody, and insufficiency of NF- κ B subunit p65 also displayed the similar results (Additional file 1: Fig. S5). Together, these results revealed that FOXM1D binds to PKM2, the NF- κ B subunits p65 and p50, further promotes their nuclear translocation, thus leading to increased VEGFA expression as regulated by both PKM2 and NF- κ B.

The Binding of FOXM1D to Importin 4 Promotes the Nuclear Translocation of PKM2 and NF- κ B

FOXM1D locates predominantly in the cytoplasm, while PKM2 and NF- κ B translocate into nucleus to regulate *VEGFA* transcription upon ectopic FOXM1D. Therefore, we further explored how FOXM1D promotes nuclear translocation of PKM2 and NF- κ B. The result of Co-IP analysis demonstrated the interaction between FOXM1A/B/CD and PKM2 (Additional file 1: Fig. S1a). Next, we employed ICC analysis to verify their localization (Fig. 6a). As reported previously [28], FOXM1B/C locate predominantly

in the nucleus while FOXM1A/D locate predominantly in the cytoplasm (Fig. 6a). Ectopic expression of all four FOXM1 isoforms did not alter the expression level of PKM2, while ectopic expression of FOXM1B/C/D, but not FOXM1A, promoted the nuclear translocation of PKM2 (Fig. 6a-b). Due to the higher nuclear PKM2 translocation, we thus observed a slight reduction in the level of PKM2 in the cytoplasm of FOXM1B/C/D- but not FOXM1A- overexpressing cells (Fig. 6b). In addition, we also found that ectopic expression of the four FOXM1 isoforms could effectively promote the nuclear translocation of endogenous NF- κ B by ICC assay (Additional file 1: Fig. S4) and Western blotting (Fig. 5f).

Next, we interrogated the mechanism by which FOXM1D promotes PKM2 and NF- κ B translocation into nucleus. Although importin- α/β are responsible for the import of many proteins from the cytoplasm to the nucleus, a host of importins related to β -importins have been described to interact with the nuclear localization signal of specific proteins and import them into the nucleus independently of importin- α . For example, importin-4 transports vitamin D receptor [46] as well as transition protein 2 [47], and importin-7 transports HIV-1 intracellular reverse transcription complexes [48] into the nucleus. Interestingly, we observed that both importin 4 and 7 were captured by FOXM1D with anti-Flag antibody (Additional file 4: Supplementary Data). Using Co-IP and ICC assays, we demonstrated that importin 4 bound to FOXM1A/D but not to FOXM1B/C (Fig. 6c-d), indicating that FOXM1B/C employed a different approach to inducing nuclear translocation of PKM2 and NF- κ B from FOXM1A/D. In addition, results of the gel chromatography experiment indicated that importin 4 universally located in fractions of 34-40 (Fig. 3d), suggesting that it binds to a variety of proteins including PKM2 and NF- κ B. Furthermore, insufficiency of importin 4 induced by specific siRNAs abrogated the effect of ectopic FOXM1D to increase *VEGFA* transcription, which most likely resulted from the subsequently reduced nuclear levels of PKM2 and NF- κ B (Fig. 6e-f). We also found that the levels of VEGFA in total lysate (Fig. 6e) decreased accordingly. These results suggest that FOXM1D promotes the nuclear translocation of PKM2 and that NF- κ B may be mediated by importin 4, thus leading to the upregulation of VEGFA.

FOXM1D Promotes VEGFA Release by Interacting with VPS11

Our study found that ectopic expression of FOXM1D remarkably increased VEGFA transcription (Fig. 5c), however, the level of VEGFA protein decreased conversely in the cell lysate (Fig. 5a) and only slightly increased in the supernatant (Fig. 5b). The above evidence did not seem enough to support the potent pro-angiogenic effect of FOXM1D (Fig. 4). We therefore interrogated the underlying mechanism for FOXM1D-dependent VEGFA extracellular release. FOXM1 has been demonstrated to interact with HSP70, a critical exosome biomarker [49]. Using Co-IP and LC/MS analysis, we previously identified that FOXM1D also interacted with VPS11 (Additional file 4: Supplementary Data), an exosome component [50]. It has been shown that VPS11 plays an important role in vesicle trafficking and fusion of lysosomes and endosomes [51]. Considering the importance of the exosome in angiogenesis [52, 53], we therefore hypothesized that FOXM1D might facilitate VEGFA release via the exosome by interacting with VPS11. Using a Co-IP assay, we first verified that anti-Flag antibody could capture the endogenous VPS11 in all of the Flag-FOXM1A/B/C/D-overexpressing HeLa cell extracts (Fig. 7a), indicating that FOXM1A/B/C/D interacted physically with VPS11 in the cell extracts. We also employed an ICC assay to detect the

subcellular co-localization of FOXM1A/B/C/D and VPS11. Due to the distinct subcellular location of VPS11 and FOXM1B/C, we failed to observe their virtual interaction (Fig. 7b). In contrast, we did observe sporadic formation of FOXM1A, while formation of FOXM1D exhibited the massive dot-like overlap with VPS11 (Fig. 7b). This finding suggested the strong involvement of FOXM1D in the formation of the exosome.

To understand the function of ectopic FOXM1D on regulating exosome and VEGFA release, we further collected the exosomes from the supernatant of vector control or FOXM1A/B/C/D-overexpressing HeLa cells, in which the cell number and supernatant volumes were same. Ectopic FOXM1A/B/C slightly elevated, while FOXM1D strongly elevated the number of exosomes in the supernatant, as determined by HSP70 and VEGFA levels (Fig. 7c). Further, VPS11 insufficiency induced by specific siRNAs (upper panel in Fig. 7d-e) failed to alter the effect of ectopic FOXM1D on increasing *VEGFA* transcription (bottom panel in Fig. 7d). However, it is possible that VPS11 insufficiency may result in exosome dysfunction, thus reducing the level of VEGFA in the exosome (Fig. 7f) and supernatant (Fig. 7g), while elevating VEGFA levels in total cell lysate (Fig. 7e). Therefore, these results suggested that FOXM1D interaction with VPS11 promoted exosome and VEGFA release.

Discussion

Adequate nutrients and rich vasculature are the prerequisites for the large tumor size associated with late stage cancer. During this process, PKM2 appears to play a convergent role through the regulation of glycometabolism, transcription, and angiogenesis. Herein, we have provided another mechanism by which PKM2 regulates this process. Through protein-protein interaction, the PKM2 tetramer assembles a heterooctamer with FOXM1D, thus significantly restraining its PK activity and oxidative phosphorylation to about 50% (Fig. 7h). In addition, PKM2 and NF- κ B were translocated together into the nucleus to regulate *VEGFA* transcription, which was mediated by the binding of FOXM1D to the PKM2 and NF- κ B complex and to the nuclear transporter importin 4. Furthermore, the increased VEGFA was secreted via the exosome to promote angiogenesis, which was interestingly mediated by another FOXM1D binding partner, VPS11, an important component of the exosome (Fig. 7h).

Among the four FOXM1 isoforms, nuclear-located FOXM1B/C are the subject of much more investigation, as they are the primary transcription factors involved in proliferation-related gene transcription. In addition, FOXM1B/C have been demonstrated to promote cancer progression through the interaction with other proteins, such as β -catenin, STAT3, SMAD3, HSP70, nucleophosmin (NPM), maternal embryonic leucine-zipper kinase (MELK), and Pin1 [54]. FOXM1D is predominantly located in the cytoplasm and is implicated in the remarkable upregulation that is seen in advanced colorectal cancer with liver metastasis, in which FOXM1D promotes EMT by interacting with and activating ROCKs [28]. By coincidence, an increase in PKM2 expression was also reported in late stage of colorectal cancer and was associated with metastasis [55]. Here, we further demonstrated that FOXM1D, acting as an adhesive protein, continues to interact with multiple proteins such as PKM2, the NF- κ B subunits of p65 and p50, importin 4, and VPS11, and thus promotes tumor glycolysis and angiogenesis. Unfortunately, the crystal

structure of FOXM1 remains unknown, most likely due to its highly flexible conformation, which thus makes it prone to interacting with multiple proteins.

Metabolic reprogramming is fundamental to cancer initiation and progression, in which PKM2 has been demonstrated to play a central role [56]. PKM2 is upregulated in most types of cancer cells, and dynamically exchanges between its tetrameric and dimeric forms. Dimeric PKM2 exhibits less PK activity and may be the main form that exists in cancer cells, thereby leading to accumulation of the glycolytic intermediates upstream of PKM2 and further providing a high level of metabolic precursors for synthetic processes. Aside from its expression level, PKM2 enzyme activity is tightly regulated by posttranslational modification, allosteric metabolic intermediates, and protein-protein interaction [57, 58]. Phosphorylation at tyrosine 105 disrupts the formation of the tetramer form by inducing FBP release, thus decreasing PKM2 enzymatic activity [35]. Acetylation at lysine 305 or 433 decreases PKM2 enzymatic activity by distinct mechanisms [7, 13]. Both FBP and serine are effective allosteric activations of PKM2 through the stabilizing of PKM2 in its active tetramer conformation [57]. Succinyl-5-aminoimidazole-4-carboxamide-1-ribose-5'-phosphate (SAICAR), an intermediate of the de novo purine nucleotide biosynthesis pathway, can stimulate PKM2's activities of both pyruvate kinase and protein kinase [59, 60]. Mucin 1-C [61] and death-associated protein kinase (DAPK) [62] activate, while promyelocytic leukemia (PML) tumor-suppressor protein [63] reduces the pyruvate kinase activity of PKM2 via protein-protein interaction. Herein, we revealed that the PKM2 domain B interacts directly with the encoded sequences of FOXM1 exon II and III, indicating that all four FOXM1 isoforms may bind to PKM2. Because PKM2 and FOXM1A/D, but not FOXM1B/C, mainly locate in the cytoplasm, we can postulate that the PK activity of PKM2 is probably regulated by FOXM1A/D. Indeed, FOXM1D causes a remarkable decrease in PKM2 enzymatic activity, while FOXM1A exerts the opposite effect. Interestingly, FOXM1 (B) has been demonstrated to promote the Warburg effect in pancreatic cancer by increasing LDHA transcription [64]. Moreover, FOXM1D, but not FOXM1A, assembles a heterooctamer with the PKM2 tetramer, therefore reducing the enzymatic activity of PKM2 by about a half, an effect that is probably due to the steric hindrance for the substrate binding. The enhanced Warburg effect mediated by FOXM1D may therefore promote cancer progression by increasing the production of metabolic precursors for synthetic processes.

PKM2 can also translocate into the nucleus and regulates gene expression, likely as dimer [18] or monomer [16, 56]. We further revealed that FOXM1D also strongly induces the nuclear translocation of PKM2 and NF- κ B via multiple protein-protein interactions, a process that was mediated by the interaction of FOXM1D with the soluble nuclear transport factor importin 4. The nuclear complex of PKM2 and NF- κ B then binds to the *VEGFA* promoter region, further increasing VEGFA expression. PKM2 insufficiency almost completely abrogates FOXM1D-induced VEGFA upregulation. After secretion, VEGFA is mainly contained in the exosome rather than in the soluble supernatant. More interestingly, FOXM1D further interacts with VPS11, and most likely also interacts with HSP70 [65], resulting in the promotion of the assembly and release of exosomes that contain VEGFA. Eventually, FOXM1D-induced VEGFA release in the exosome strongly promotes tumor angiogenesis and progression. It should be noted that when compared with the proliferation-specific transcription factor FOXM1B [30, 66], FOXM1D induced

significantly slower tumor growth in tumor-bearing mice, although it could potentially promote angiogenesis. This finding indicated that blood vessels might be not enough to support tumor growth and therefore anti-angiogenic drugs alone might be not be sufficient to curb cancer establishment and growth.

FOXM1 plays a critical role in each of the steps of tumor initiation, progression, metastasis, and treatment [67–69]. It is thus being acknowledged in all hallmarks of cancer with various mechanisms [70]. FOXM1, referred to as FOXM1B probably and FOXM1C in most cases, has been identified to be strongly upregulated in almost all types of tumors and as a major predictor for cancer prognosis by gene landscape analysis [25, 26, 31, 71]. However, it seems challengeable to explain the importance of FOXM1 in cancer by only describing the ability of FOXM1 (FOXM1B/C) to regulate the transcription of over 200 target genes that are primarily involved in cell proliferation[29, 30]. Alternative splicing may diversify the functional characteristics of some genes even with minor variants of each other, thus contributing to the functional complexity that results from the diverse sequence and subcellular distribution on the protein level [72]. Herein, our findings have provided a new insight into the PKM2-induced tumor glycolysis and angiogenesis that was potentiated by multiple protein-protein interactions mediated by FOXM1D, and suggest that FOXM1 may be a promising target for cancer therapeutics.

Conclusion

In conclusion, FOXM1D binds to tetrameric PKM2 and assembles a heterooctamer in the presence of FBP, restraining PKM2 metabolic activity and promoting aerobic glycolysis. Furthermore, FOXM1D interacts with PKM2 and NF- κ B and induces their nuclear translocation and promoting the transcription and secreted of *VEGFA*, eventually promoting tumor angiogenesis. Therefore, we hope our study provides another insight into the role of PKM2 in the regulation of glycolysis and angiogenesis, and further proves FOXM1 as the potential drug target for cancer therapy.

Experimental procedures

Cell culture and reagents

All cell lines were purchased from the Type Culture Collection Cell Bank, Chinese Academy of Sciences. HEK 293T cells were grown in DMEM medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. HeLa cells were grown in 1640 medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. SW480 cells were grown in L-15 medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. LoVo cells were grown in F-12K Medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. Human umbilical vein endothelial cells (HUVEC) were grown in F-12K Medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. All cells were cultured at 37 °C with 5% CO₂. PKM2 was purchased from Abcam (Abcam, ab89364, Cambridge, MA). All antibodies used in this study are listed in Additional file 2: Supplemental Table S1.

Cell transfection

HeLa or 293FT Cells were planted in a 10cm dish for 50% density the day before transfection. Transfection could be performed when the cells have grown to a density of 70%. Plasmid or siRNA were mixed with Lipofectamin3000 (invitrogen, Carlsbad, CA) based on the manufacture's guide. Incubate for 10min at room temperature and then added them into the cell culture dish. Cells were collected 48h after transfection.

Western blot analysis

Cells were harvested by scraping into an SDS sample buffer containing a cocktail of protease inhibitors and PhosSTOP Phosphatase Inhibitor (Roche, Pleasanton, CA). Western blotting was conducted according to the standard procedure. The antibody used in this study are listed in Additional file 2: Supplemental Table S1.

Extracellular acidification (ECAR) and oxygen consumption rate (OCR) assays

The ECAR and cellular OCR were determined using the Seahorse XFe 96 Extracellular Flux Analyzer (Seahorse Bioscience, North Billerica, MA). Experiments were performed according to the manufacturer's protocols. ECAR and OCR were examined using the Seahorse XF Glycolysis Stress Test Kit and the Seahorse XF Cell Mito Stress Test Kit, respectively. Briefly, 1×10^4 cells per well were seeded into a Seahorse XF 96 cell culture microplate. Baseline measurements were taken, after which glucose, the oxidative phosphorylation inhibitor oligomycin, and the glycolytic inhibitor 2-DG were sequentially injected into each well at indicated time points for the measurement of ECAR. Oligomycin, the reversible inhibitor of oxidative phosphorylation FCCP (p-trifluoromethoxy carbonyl cyanide phenylhydrazine), and the mitochondrial complex I inhibitor rotenone, plus the mitochondrial complex III inhibitor antimycin A (Rote/AA) were sequentially injected for the measurement of OCR. Data were assessed using the Seahorse XF-96 Wave software. The OCR is shown in pmols/minute and ECAR in mpH/ minute.

Co-immunoprecipitation (co-IP) assays

HeLa and HEK293T cells were seeded in 10-cm dishes, and HEK293T cells were co-transfected with the indicated plasmids. Two days following the transfection, the cells were lysed and co-immunoprecipitated using the antibody or label tagged affinity gel, according to the manufacturer's instructions. The immunoprecipitations were washed four times with lysis buffer and stored at -80°C until needed, or were directly boiled with sigma sample buffer and subsequent SDS-PAGE and silver staining or western blotting, as described above.

Immunofluorescence (IF) staining and confocal microscopy

HeLa cells grown on the culture slides (BD Biosciences, San Jose, CA) were maintained in a 24-well cell culture cluster and transfected using Lipofectamine 3000. After incubation for 48 h, the cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100 in PBS for 5-8 min at room

temperature followed by incubation in blocking buffer supplemented with 1% BSA for 1 h at room temperature. The cells were then incubated with FLAG mouse monoclonal antibody (1:200 dilution) and PKM2/VPS11 rabbit monoclonal antibody (1:200 dilution) at 4 °C overnight. The next day the cells were washed three times in PBS and then stained with Alexa Fluor 488 Goat Anti-Mouse IgG and Alexa Fluor 594 Goat Anti-Rabbit IgG (1:5000 dilution, Invitrogen) for 2h at room temperature. After incubation with DAPI to stain the nuclei, the cells were visualized with a confocal laser scanning microscope (Olympus Corporation, Tokyo, Japan).

Glutathione S-transferase (GST) pull-down and in vitro binding assays

Bacterial-expressed GST–FOXM1D or control GST bound to MagneGST glutathione particles was incubated with PKM2-transfected HEK293T cell lysates for 1 h at 4 °C using the MagneGST Pull-Down System (Millipore), according to the manufacturer's instructions. The washed complexes were eluted by boiling in SDS sample buffer before separation by SDS–PAGE, after which the interactions were analyzed by western blotting.

Protein Cross-linking

Cells from 10mm dishes were digested and lysed in 500 µL of lysis buffer with protease inhibitor cocktail at 4°C for 40 min. The lysates were centrifuged at 12000Xg for 10 minutes. The supernatants were drawn into two tubes (200 µL each), (one for cross-link and one for control). A preparation of 0.5% glutaraldehyde solution (Solarbio #G8090) (10 µL) was added to the lysate to a final concentration of 0.0025wt %. The solution was mixed well and incubated on ice for 5min. Then 10 µL of 1M Glycine was added for 15 min at room temperature. Finally, 50 µL of 5× loading buffer was added to the tube and the lysates were boiled at 100°C.

Gel chromatography

Cells were seeded in a 10 cm dish. When a concentration of 80% to 90% was achieved, the cells were harvested and washed 3 times with ice-cold PBS. The lysis buffer contained a protease inhibitor and a phosphatase inhibitor cocktail and lysates were incubated for 1 h before centrifugation at 13,000 rpm for 15 min to remove cell debris. The gel chromatography column (Superdex 200; Amersham Biosciences) was washed and equilibrated with cold PBS (4°C) before passing the extracts over the gel chromatography column. The flow rate was 0.3 mL/min. Fractions were collected at 0.3 mL per tube and analyzed by western blot. The molecular mass was determined by a Gel Chromatography Calibration Kit HMW (GE Healthcare). For each protein subjected to the polymer formation experiment, 60 µg were used per test, and were co-incubated overnight prior to the gel chromatography assay.

Protein Expression and Purification

The 293FT cells were transfected with Flag-tagged FOXM1A, FOXM1D, or FBP plasmid. Two days later, the Flag-tagged proteins were purified from the cell lysates using Flag-tagged beads (Selleck, Houston, TX), according to the manufacturer's instructions. Briefly, 10 mg/mL Flag peptide was used for

competitive binding, in which the volume of the peptide buffer was at least 5-fold larger than the volume of beads. To achieve highly pure proteins, the eluted proteins were further purified by gel chromatography.

Tumor tissue microangiography

Microangiography for blood vessels was performed using beamline BL13W1, an X-ray imaging and biomedical application station at the Shanghai Synchrotron Radiation Facility (SSRF) in China. The maximum light size of the beam was 45 mm (horizontal) by 5 mm (vertical) at the object position at 20 keV. All animals were anesthetized by intraperitoneal injection of ketamine (200 mg/kg) (Ketanest; Pfizer, Karlsruhe, Germany). The image contrast agent barium sulfate was suspended in glycerol (50% water solution; a concentration of 0.5 g/mL) and injected into the left ventricle of nude mice. Serial images of tumor blood vessels were then recorded at the SSRF.

Quantitative real-time PCR (qRT-PCR)

Total RNA in cells was extracted with Trizol reagent (Invitrogen, Grand Island, NY) then transcribed into cDNA using PrimeScript™ One Step RT-PCR Kits (Takara Biomedical Technology, Beijing, China). The qRT-PCR was carried out using TB Green® Premix Ex Taq™ (Takara Biomedical Technology, Beijing, China) as the user guide. Primer sequences are listed in Additional file 3: Supplemental Table S2. We used the ACTB gene encoding β -actin as the endogenous control, and the samples were analyzed in triplicate.

Chromatin Immunoprecipitation (ChIP)

Chromatin was immunoprecipitated according with the EZ-Magna G Chromatin Immunoprecipitation kit's (Millipore® Darmstadt, GER) user guide. Occupancy was assessed by qRT-PCR for samples precipitated with a specific antibody versus samples precipitated with the control immunoglobulin G (12–371, Millipore® Darmstadt, GER) using the specific primers indicated in the Additional file 3: Supplemental Table S2.

Human umbilical vein endothelial cell (HUVEC) tube formation assay

HeLa cells with ectopic FOXM1A/B/C/D expression were cultured in complete medium for 12 h, and then serum-free medium for 24 h, after which point the supernatants were collected. Matrigel (BD Biosciences, Franklin Lakes, NJ) (50 μ L) was pipetted into each well of a 96-well plate and polymerized for 30 min at 37°C in incubator. HUVECs (4×10^4 cells) were suspended in 100 μ L of the above supernatants and distributed into each well. After incubation for 5 h at 37°C, images were taken with a 100 $\times$ and 400 $\times$ phase contrast microscope. Each condition was assessed at least in triplicate in three independent experiments.

Measurement of VEGFA in the supernatant

The cells were cultured in a 6-well plate at a concentration of 1×10^6 cells per well for 24 h, after which point the supernatant was harvested to measure VEGFA concentration using a commercially available

fluorescence-based assay kit (ARIGO, ARG81305, Taiwan, China).

Measurement of Pyruvate Kinase (PK) activity

The PK activity was measured using a PK activity assay kit (Solarbio, BC0545-shanghai-China) based on the manufacture's guide.

Exosome Collection

Cells were plated in a 10cm dish with complete medium. When the cell density reached above 95%, the culture medium was changed to serum-free and collected after 12 h culture. Exosomes were collected by filtration of the supernatant with a 0.22 μ m membrane and 1×10^6 g supernatant centrifugation for 2 h.

Quantification and Statistical Analysis

The statistics was performed with GraphPad Prism 7.0 (GraphPad Software, La Jolla, CA). The results were presented as mean $\pm$ SD or mean $\pm$ SEM, as indicated in the figure legends. Differences in parametric data between two groups were evaluated by Student's *t*-test (two-tailed). A *p* value less than 0.05 was considered significant and the level of significance was indicated as ns, not statistically significant; * *p* < 0.05 and ** *p* < 0.01, *** *p* < 0.001 vs. control.

Abbreviations

FOXM1: Forkhead box M1; Co-IP: coimmunoprecipitation; IF: Immunofluorescence; ECAR: Extracellular acidification; OCR: oxygen consumption rate; HUVEC: Human umbilical vein endothelial cell; PK: Pyruvate kinase; PEP: phosphoenolpyruvate; ADP: adenosine diphosphate; ATP: adenosine triphosphate; EGF: epidermal growth factor; VEGFA: vascular endothelial growth factor-A; HIF-1 α : Hypoxia-inducible factor 1; EMT: epithelial–mesenchymal transition; GST: glutathione S-transferase; PTM: post-translation modification; qRT-PCR: quantitative real-time PCR; MELK: maternal embryonic leucine-zipper kinase; SAICAR: Succinyl-5-aminoimidazole-4-carboxamide-1-ribose-5'-phosphate; DAPK: death-associated protein kinase; PML: promyelocytic leukemia;

Declarations

Availability of data and material

The datasets used or analysed during the current study are available from the corresponding author on reasonable request.

Competing Interests

The authors declare no competing financial interests.

Funding

This research was supported by the National Natural Science Foundation of China (81872354 and 81790254) and the Major State Basic Research Development Program of China (2013CB910802) to W.H.

Author Contributions

W.H. conceived and supervised the project; W.H. and W.Z. wrote the manuscript; W.Z., X.Z., and S.H. performed most of the experiments and analyzed the data, with assistance from J.C., P.D., Q.W., Luying Li, X.L., Ling Li, P.Z. and D.Z., in which X.Z. and S.H. performed, and W.H. and J. W. supervised the microangiography experiment. QY.L. and J.W. contributed ideas.

Acknowledgements

Not applicable.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Authors' information

¹ Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 200032, China. ² Department of Breast Surgery, Breast Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai 200032, China. ³ Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China

References

1. Folkman J. Role of angiogenesis in tumor growth and metastasis. *Semin Oncol.* 2002;29:15–8.
2. Warburg O. On the origin of cancer cells. *Science.* 1956;123:309–14.
3. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science.* 2009;324:1029–33.
4. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. *Nat Rev Cancer.* 2011;11:85–95.
5. Hsu PP, DM, Sabatini. Cancer cell metabolism: Warburg and beyond. *Cell.* 2008;134:703–7.
6. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. *Nat Rev Cancer.* 2011;11:325–37.
7. Lv L, Xu YP, Zhao D, Li FL, Wang W, Sasaki N, et al. Mitogenic and oncogenic stimulation of K433 acetylation promotes PKM2 protein kinase activity and nuclear localization. *Mol Cell.* 2013;52:340–

52.

8. Desai S, Ding M, Wang B, Lu Z, Zhao Q, Shaw K, et al. Tissue-specific isoform switch and DNA hypomethylation of the pyruvate kinase PKM gene in human cancers. *Oncotarget*. 2014;5:8202–10.
9. Calabretta S, Bielli P, Passacantilli I, Piloizzi E, Fendrich V, Capurso G, et al. Modulation of PKM alternative splicing by PTBP1 promotes gemcitabine resistance in pancreatic cancer cells. *Oncogene*. 2016;35:2031–9.
10. Mazurek S. Pyruvate kinase type M2: a key regulator of the metabolic budget system in tumor cells. *Int J Biochem Cell Biol*. 2011;43:969–80.
11. Takenaka M, Yamada K, Lu T, Kang R, Tanaka T, Noguchi T. Alternative splicing of the pyruvate kinase M gene in a minigene system. *Eur J Biochem*. 1996;235:366–71.
12. Mazurek S, Boschek CB, Hugo F, Eigenbrodt E. Pyruvate kinase type M2 and its role in tumor growth and spreading. *Semin Cancer Biol*. 2005;15:300–8.
13. Lv L, Li D, Zhao D, Lin R, Chu Y, Zhang H, et al. Acetylation targets the M2 isoform of pyruvate kinase for degradation through chaperone-mediated autophagy and promotes tumor growth. *Mol Cell*. 2011;42:719–30.
14. Hoshino A, Hirst JA, Fujii H. Regulation of cell proliferation by interleukin-3-induced nuclear translocation of pyruvate kinase. *J Biol Chem*. 2007;282:17706–11.
15. Yang W, Zheng Y, Xia Y, Ji H, Chen X, Guo F, et al. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. *Nat Cell Biol*. 2012;14:1295–304.
16. Yang W, Lu Z. Nuclear PKM2 regulates the Warburg effect. *Cell Cycle*. 2013;12:3154–8.
17. Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W, et al. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. *Nature*. 2011;480:118–22.
18. Gao X, Wang H, Yang JJ, Liu X, Liu ZR. Pyruvate kinase M2 regulates gene transcription by acting as a protein kinase. *Mol Cell*. 2012;45:598–609.
19. Vasudev NS, AR, Reynolds. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. *Angiogenesis*. 2014;17:471–94.
20. Luo W, Hu H, Chang R, Zhong J, Knabel M, O'Meally R, et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. *Cell*. 2011;145:732–44.
21. Palsson-McDermott EM, Curtis AM, Goel G, Lauterbach MA, Sheedy FJ, Gleeson LE, et al. Pyruvate kinase M2 regulates Hif-1alpha activity and IL-1beta induction and is a critical determinant of the warburg effect in LPS-activated macrophages. *Cell Metab*. 2015;21:65–80.
22. Azoitei N, Becher A, Steinestel K, Rouhi A, Diepold K, Genze F, et al. PKM2 promotes tumor angiogenesis by regulating HIF-1alpha through NF-kappaB activation. *Mol Cancer*. 2016;15:3.
23. Xu Q, Liu LZ, Yin Y, He J, Li Q, Qian X, et al. Regulatory circuit of PKM2/NF-kappaB/miR-148a/152-modulated tumor angiogenesis and cancer progression. *Oncogene*. 2015;34:5482–93.
24. Kalin TV, Ustiyan V, Kalinichenko VV. Multiple faces of FoxM1 transcription factor: lessons from transgenic mouse models. *Cell Cycle*. 2011;10:396–405.

25. Wierstra I. FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy. *Adv Cancer Res.* 2013;119:191–419.
26. Gentles AJ, Newman AM, Liu CL, Bratman SV, Feng W, Kim D, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. *Nat Med.* 2015;21:938–45.
27. Wierstra I, Alves. FOXM1, a typical proliferation-associated transcription factor. *Biol Chem.* 2007;388:1257–74.
28. Zhang X, Zhang L, Du Y, Zheng H, Zhang P, Sun Y, et al. A novel FOXM1 isoform, FOXM1D, promotes epithelial-mesenchymal transition and metastasis through ROCKs activation in colorectal cancer. *Oncogene.* 2017;36:807–19.
29. Wierstra I. The transcription factor FOXM1 (Forkhead box M1): proliferation-specific expression, transcription factor function, target genes, mouse models, and normal biological roles. *Adv Cancer Res.* 2013;118:97–398.
30. Myatt SS, E W Lam. The emerging roles of forkhead box (Fox) proteins in cancer. *Nat Rev Cancer.* 2007;7:847–59.
31. Li M, Sun Q, Wang X. Transcriptional landscape of human cancers. *Oncotarget.* 2017;8:34534–51.
32. Kong X, Li L, Li Z, Le X, Huang C, Jia Z, et al. Dysregulated expression of FOXM1 isoforms drives progression of pancreatic cancer. *Cancer Res.* 2013;73:3987–96.
33. Wang P, Sun C, Zhu T, Xu Y. Structural insight into mechanisms for dynamic regulation of PKM2. *Protein Cell.* 2015;6:275–87.
34. Sun Q, Chen X, Ma J, Peng H, Wang F, Zha X, et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. *Proc Natl Acad Sci U S A.* 2011;108:4129–34.
35. Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, Lythgoe K, et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. *Sci Signal.* 2009;2:ra73.
36. Christofk HR, Vander Heiden MG, Wu N, Asara JM, L C Cantley. Pyruvate kinase M2 is a phosphotyrosine-binding protein. *Nature.* 2008;452:181–6.
37. Dayton TL, Jacks T, Vander Heiden MG. PKM2, cancer metabolism, and the road ahead. *EMBO Rep.* 2016;17:1721–30.
38. Dombrackas JD, Santarsiero BD, Mesecar AD. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. *Biochemistry.* 2005;44:9417–29.
39. Polet F, O, Feron. Endothelial cell metabolism and tumour angiogenesis: glucose and glutamine as essential fuels and lactate as the driving force. *J Intern Med.* 2013;273:156–65.
40. Burns JS, G, Manda. Metabolic Pathways of the Warburg Effect in Health and Disease: Perspectives of Choice, Chain or Chance. *Int J Mol Sci.* 2017;18.
41. Lee HW, Yu P, Simons M. Recent advances in understanding lymphangiogenesis and metabolism. *F1000Res.* 2018;7.

42. Jin W, Chen BB, Li JY, Zhu H, Huang M, Gu SM, et al. TIEG1 inhibits breast cancer invasion and metastasis by inhibition of epidermal growth factor receptor (EGFR) transcription and the EGFR signaling pathway. *Mol Cell Biol*. 2012;32:50–63.
43. Hicklin DJ, LM, Ellis. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. *J Clin Oncol*. 2005;23:1011–27.
44. Zhang Y, Zhang N, Dai B, Liu M, Sawaya R, Xie K, et al. FoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cells. *Cancer Res*. 2008;68:8733–42.
45. Jin B, Wang C, Li J, Du X, Ding K, J Pan. Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/beta-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia. *Clin Cancer Res*. 2017;23:789–803.
46. Miyauchi Y, Michigami T, Sakaguchi N, Sekimoto T, Yoneda Y, Pike JW, et al. Importin 4 is responsible for ligand-independent nuclear translocation of vitamin D receptor. *J Biol Chem*. 2005;280:40901–8.
47. Pradeepa MM, Manjunatha S, Sathish V, Agrawal S, M R Rao. Involvement of importin-4 in the transport of transition protein 2 into the spermatid nucleus. *Mol Cell Biol*. 2008;28:4331–41.
48. Fassati A, Gorlich D, Harrison I, Zaytseva L, Mingot JM. Nuclear import of HIV-1 intracellular reverse transcription complexes is mediated by importin 7. *EMBO J*. 2003;22:3675–85.
49. Greening DW, Gopal SK, Xu R, Simpson RJ, Chen W. Exosomes and their roles in immune regulation and cancer. *Semin Cell Dev Biol*. 2015;40:72–81.
50. Keerthikumar S, Chisanga D, Ariyaratne D, Saffar HA, Anand S, Zhao K, et al. ExoCarta: A Web-Based Compendium of Exosomal Cargo. *J Mol Biol*. 2016;428:688–92.
51. Plemel RL, Lobingier BT, Brett CL, Angers CG, Nickerson DP, Paulsel A, et al. Subunit organization and Rab interactions of Vps-C protein complexes that control endolysosomal membrane traffic. *Mol Biol Cell*. 2011;22:1353–63.
52. Salem KZ, Moschetta M, Sacco A, Imberti L, Rossi G, Ghobrial IM, et al. Exosomes in Tumor Angiogenesis. *Methods Mol Biol*. 2016;1464:25–34.
53. Todorova D, Simoncini S, Lacroix R, Sabatier F, Dignat-George F. Extracellular Vesicles in Angiogenesis *Circ Res*. 2017;120:1658–73.
54. Gartel AL. FOXM1 in Cancer: Interactions and Vulnerabilities. *Cancer Res*. 2017;77:3135–9.
55. Zhou CF, Li XB, Sun H, Zhang B, Han YS, Jiang Y, et al. Pyruvate kinase type M2 is upregulated in colorectal cancer and promotes proliferation and migration of colon cancer cells. *IUBMB Life*. 2012;64:775–82.
56. Yang WZ, Lu. Regulation and function of pyruvate kinase M2 in cancer. *Cancer Lett*. 2013;339:153–8.
57. Luo W, GL, Semenza. Emerging roles of PKM2 in cell metabolism and cancer progression. *Trends Endocrinol Metab*. 2012;23:560–6.

58. Li Z, Yang P, Li Z. The multifaceted regulation and functions of PKM2 in tumor progression. *Biochim Biophys Acta*. 2014;1846:285–96.
59. Keller KE, Tan IS, Lee YS. SAICAR stimulates pyruvate kinase isoform M2 and promotes cancer cell survival in glucose-limited conditions. *Science*. 2012;338:1069–72.
60. Keller KE, Doctor ZM, Dwyer ZW, Lee YS. SAICAR induces protein kinase activity of PKM2 that is necessary for sustained proliferative signaling of cancer cells. *Mol Cell*. 2014;53:700–9.
61. Kosugi M, Ahmad R, Alam M, Uchida Y, Kufe D. MUC1-C oncoprotein regulates glycolysis and pyruvate kinase M2 activity in cancer cells. *PLoS One*. 2011;6:e28234.
62. Mor I, Carlessi R, Ast T, Feinstein E, Kimchi A. Death-associated protein kinase increases glycolytic rate through binding and activation of pyruvate kinase. *Oncogene*. 2012;31:683–93.
63. Shimada N, Shinagawa T, Ishii S. Modulation of M2-type pyruvate kinase activity by the cytoplasmic PML tumor suppressor protein. *Genes Cells*. 2008;13:245–54.
64. Cui J, Shi M, Xie D, Wei D, Jia Z, Zheng S, et al. FOXM1 promotes the warburg effect and pancreatic cancer progression via transactivation of LDHA expression. *Clin Cancer Res*. 2014;20:2595–606.
65. Halasi M, Varaljai R, Benevolenskaya E, Gartel AL. A Novel Function of Molecular Chaperone HSP70: SUPPRESSION OF ONCOGENIC FOXM1 AFTER PROTEOTOXIC STRESS. *J Biol Chem*. 2016;291:142–8.
66. Wang IC, Chen YJ, Hughes D, Petrovic V, Major ML, Park HJ, et al. Forkhead box M1 regulates the transcriptional network of genes essential for mitotic progression and genes encoding the SCF (Skp2-Cks1) ubiquitin ligase. *Mol Cell Biol*. 2005;25:10875–94.
67. Koo CY, Muir KW, Lam EW. FOXM1: From cancer initiation to progression and treatment. *Biochim Biophys Acta*. 2012;1819:28–37.
68. Halasi M, AL, Gartel. Targeting FOXM1 in cancer. *Biochem Pharmacol*. 2013;85:644–52.
69. Raychaudhuri PHJ, Park. FoxM1: a master regulator of tumor metastasis. *Cancer Res*. 2011;71:4329–33.
70. Halasi M, AL, Gartel.. FOX(M1) news—it is cancer. *Mol Cancer Ther*. 2013;12:245–54.
71. Li L, Wu D, Yu Q, Li L, Wu P. Prognostic value of FOXM1 in solid tumors: a systematic review and meta-analysis. *Oncotarget*. 2017;8:32298–308.
72. Yang X, Coulombe-Huntington J, Kang S, Sheynkman GM, Hao T, Richardson A, et al. Widespread Expansion of Protein Interaction Capabilities by Alternative Splicing. *Cell*. 2016;164:805–17.

Figures

Figure 1

The physical interaction between FOXM1D and PKM2. **a** Identification of FOXM1D-binding proteins, including PKM2, NF- κ B subunit p65, VPS11, and importin 4 by Co-IP using rabbit anti-Flag antibody or the rabbit control IgG isotype antibody, and further by LC-MS/MS analysis. See also Additional file 4: Supplementary Data. **b** Verification of the interaction between Flag-FOXM1D and HA-PKM2 by Co-IP. Top, anti-Flag antibody captured HA-PKM2; Bottom, anti-HA antibody captured Flag-FOXM1D. **c** GST-FOXM1D binds to HA-PKM2 as determined by GST pull-down assay and immunoblotting assay using anti-HA and anti-PKM2 antibodies. **d** Schematic diagram of the truncated mutants of PKM2 based on their structural domain. **e** PKM2 mutants A, B, and C bound to FOXM1D as revealed by Co-IP assay. **f** GST-FOXM1D binds to PKM2 B, but not the A1 domain, which were tagged with HA and separately expressed into 293T cells, as determined by GST pull-down assay. **g** Schematic diagram of the truncated mutants of FOXM1D based on exons. The related constructs only contained the coding fragments in Exon II and VIII, therefore the single quotation marks were added. **h** FOXM1D exon II and III encoded region binds to PKM2 as

revealed by Co-IP assay. Flag-FOXM1D mutants A, B, and D that bound to HA-PKM2 share the common exon II and III. FL, full length.

Figure 2

FOXM1D promotes glycolysis. a, b ECAR (a) and OCR (b) assays in HeLa cells stably overexpressing FOXM1A/B/C/D or vector control. The ectopic expression of only FOXM1D enhanced glycolytic activity as determined by ECAR, while it impaired mitochondrial function as determined by OCR. c, d ECAR (c) and OCR (d) assays in SW-480 cells stably overexpressing FOXM1D or vector control, and in LoVo cells transfected with siRNA specific against FOXM1D or scramble siRNA. The ectopic expression of FOXM1D enhanced glycolytic activity, while it impaired mitochondrial function. In contrast, the insufficiency of FOXM1D played the opposite role.

Figure 3

Tetrameric PKM2 assembles a heterooctamer with FOXM1D, thus reducing PK activity. **a** The phosphorylation and acetylation levels of PKM2 in HeLa cells with ectopic expression of FOXM1A/D. **b** Immunoassays detected that Ectopic FOXM1D, but not FOXM1A, induced the emergence of a macromolecular protein complex (black arrow) containing PKM2 in cross-linked samples from HeLa cells, thus altering the composition of PKM2 monomer and polymers. **c** The effect of PKM2 insufficiency on

the formation of the FOXM1D and PKM2 complex. Up panel: the ectopic expression of FOXM1A/D using regular samples. Bottom panel: PKM2 insufficiency by specific siRNAs using cross-linking samples reduced the FOXM1D-containing (black arrow), but not the FOXM1A-containing complex, leading to a new FOXM1 band (arrowhead). d Identification of the potential complex of FOXM1D and PKM2 in HeLa cells with ectopic expression of FOXM1D by gel chromatography and immunoblotting. FOXM1D assembles a heterooctamer with PKM2, predicted by the molecular weight. The fraction numbers, elution of molecular weight markers with arrows, and PKM2 monomer/polymers are indicated. e The PK activity of individual fractions from HeLa cells that were ectopic expression with vector, FOXM1A, or FOXM1D. f, g Identification of the interaction between FOXM1D and PKM2 in the absence (f) and presence (g) of FBP by gel chromatography. The three purified proteins were loaded in equal amounts (60 μ g). h The measurement of PK activity in the different indicated mixtures. Each '+' represents 10 μ g of protein, thus 10 μ g of FOXM1/10 μ g PKM2, 20 μ g FOXM1/10 μ g PKM2, and 30 μ g FOXM1/10 μ g PKM2 is about 0.665, 1.33, and 2, respectively, in molar ratio. Data represent the mean $\pm$ SD from 3 independent experiments. * p <0.05; ** p <0.01; and **** p <0.0001 vs. control

Figure 4

FOXM1D promotes angiogenesis. a-c The supernatant of cells with ectopic expression of FOXM1D, but not of FOXM1A/B/C, promoted HUVEC tube formation. The representative images (a) and the quantitative results of total meshes' area (b) and total length (c). Scale bar, 200 μ m (left panel in a) or 100 μ m (right panel in a). Data represent the mean $\pm$ SD, n=3, * p <0.05, ** p <0.01, and *** p <0.001. d The representative images of tumor blood vessels in the mice bearing HeLa cells stably overexpressing

control, FOXM1B, or FOXM1D achieved by a microangiographic technique. Scale bar, 450 μ m. e The quantitative results of microvessel diameter assessment. Three groups were divided because of the diameter. Data represent mean $\pm$ SD, n=3, * p<0.05, ** p<0.01, and *** p<0.001.

Figure 5

FOXM1D increases VEGFA expression by inducing the nuclear translocation of PKM2 and NF- κ B. a-b VEGFA protein levels in the total lysates (a) and supernatant (b) of HeLa cells with ectopic expression of FOXM1A/B/C/D. c VEGFA mRNA levels in HeLa cells with ectopic expression of FOXM1A/B/C/D. d-e The interaction among FOXM1A/B/C/D, NF- κ B (p65 in d or p50 in e), and PKM2. FOXM1A/B/C/D bound to PKM2 and p65 (d), while only FOXM1A, and especially FOXM1D, bound to p50 (e). f FOXM1A/B/C/D enhanced p65 and p50 nuclear translocation. g The mRNA levels of PKM1/2 after PKM2 specific siRNAs treatment. Their protein levels in cell lysate are shown in (j). h-j Insufficiency of PKM2 via siRNAs abrogated the FOXM1D-induced increase of VEGFA in mRNA (h) and protein (supernatant in i and cell

lysate in j) levels in HeLa cells. Data represent the mean $\pm$ SD from 3 independent experiments. k-m The specific antibody against PKM2, p50, or p65 could capture the fragment containing the same response element in the VEGFA promoter region (k). The binding site was predicted in bold sequences using MatInspector software (GenomatixMunichGermany), in which the critical binding site was further highlighted in italic, and was amplified by the same specific primers (Additional file 3: Supplementary Table S2) using PCR in the ChIP assay (l). The quantitative data are also shown (m). Data represent the means $\pm$ SD, n=3, ** p<0.01, *** p<0.001, and **** p<0.0001 vs. control.

Figure 6

Importin 4 mediates FOXM1D-induced nuclear translocation of PKM2 and NF-κB and the resultant VEGFA upregulation via interaction with FOXM1D. a The subcellular co-localization of Flag-FOXM1A/B/C/D and HA-PKM2. The nuclear translocation of PKM2 increased upon the ectopic expression of FOXM1B/C/D,

but not of FOXM1A, as determined by ICC assay in HeLa cells (white arrows). The interaction of FOXM1A/D with PKM2 was predominantly located in the cytoplasm, while that of FOXM1B/C with PKM2 existed mainly in the nucleus. Scale bar, 25 μ m. b The subcellular detection of PKM2 by immunoblotting in HeLa cells with the ectopic expression of FOXM1A/B/C/D. The ectopic expression of FOXM1A/B/C/D failed to alter the PKM2 level (up panel in b). However, the ectopic expression of FOXM1B/C/D, but not of FOXM1A, promoted the nuclear translocation of PKM2 (middle panel in b) along with a slight decrease in cytoplasmic PKM2 (bottom panel in b). c-d FOXM1A/D, but not FOXM1B/C, bound strongly to importin 4, as determined by ICC (c) and Co-IP (d) assays. Scale bar, 10 μ m. e Insufficiency of importin 4 induced by specific siRNAs abrogated the effect of FOXM1D on the promotion of VEGFA transcription and suppresses FOXM1D-induced nuclear translocation of PKM2 and NF- κ B. f Insufficiency of importin 4 thus further reduced VEGFA levels in the total lysate. Data represent the mean $\pm$ SD from independent experiments. * $p < 0.05$; ** $p < 0.01$; and *** $p < 0.001$ vs. control.

Figure 7

FOXM1D promotes the secretion of VEGFA-containing exosomes by interacting with VPS11. a-b Flag-FOXM1A/B/C/D all interacted with endogenous VPS11, as identified by Co-IP (a) and ICC (b) assays. FOXM1D binding to VPS11 displayed stronger affinity than FOXM1A/B/C (a), and FOXM1A/D, but not FOXM1B/C, co-localized with VPS11 in the cytoplasm (b). Scale bar, 10 μ m. (c) FOXM1D strongly promoted the secretion of VEGFA-containing exosomes. A serum-free medium was changed and cultured

for 12h before collection. d Insufficiency of VPS11 induced by specific siRNAs did not alter VEGFA transcription. e-g Insufficiency of VPS11 increased the accumulation of VEGFA in the total lysate (e), while it reduced VEGFA levels in the supernatant (f) and exosome (g). h Working model for FOXM1 potentiating PKM2-mediated tumor glycolysis and angiogenesis. Data represent the mean $\pm$ SD from 3 independent experiments. * $p < 0.05$; ** $p < 0.01$; and **** $p < 0.0001$ vs. control.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Additionalfile3SupplementalTableS2.pdf](#)
- [Additionalfile3SupplementalTableS2.pdf](#)
- [Additionalfile3SupplementalTableS2.pdf](#)
- [Additionalfile4AntiFOXM1DCoIPLCMS.xlsx](#)
- [Additionalfile4AntiFOXM1DCoIPLCMS.xlsx](#)
- [Additionalfile4AntiFOXM1DCoIPLCMS.xlsx](#)
- [Additionalfile2SupplementalTableS1.pdf](#)
- [Additionalfile2SupplementalTableS1.pdf](#)
- [Additionalfile2SupplementalTableS1.pdf](#)
- [Additionalfile1SupplementalFigures.pdf](#)
- [Additionalfile1SupplementalFigures.pdf](#)
- [Additionalfile1SupplementalFigures.pdf](#)